Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Moodys
AstraZeneca
Federal Trade Commission
Deloitte
Teva
Argus Health
Cipla
Covington

Generated: September 22, 2018

DrugPatentWatch Database Preview

Mylan Institutional Company Profile

« Back to Dashboard

What is the competitive landscape for MYLAN INSTITUTIONAL, and what generic alternatives to MYLAN INSTITUTIONAL drugs are available?

MYLAN INSTITUTIONAL has fifty-seven approved drugs.

There is one US patent protecting MYLAN INSTITUTIONAL drugs.

Drugs and US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Institutional OCTREOTIDE ACETATE (PRESERVATIVE FREE) octreotide acetate INJECTABLE;INJECTION 079198-002 Feb 10, 2011 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional HYDRALAZINE HYDROCHLORIDE hydralazine hydrochloride INJECTABLE;INJECTION 204680-001 Apr 28, 2016 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional CHLOROTHIAZIDE SODIUM chlorothiazide sodium INJECTABLE;INJECTION 202493-001 Jun 18, 2014 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional KETAMINE HYDROCHLORIDE ketamine hydrochloride INJECTABLE;INJECTION 076092-003 Oct 25, 2002 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional NALOXONE HYDROCHLORIDE naloxone hydrochloride INJECTABLE;INJECTION 205014-001 Jun 29, 2016 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Mylan Institutional BIVALIRUDIN bivalirudin INJECTABLE;INTRAVENOUS 202471-001 Jun 1, 2018 AP RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Mylan Institutional

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 5,466,700*PED ➤ Try a Free Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-003 Jul 12, 1996 5,866,591*PED ➤ Try a Free Trial
Mylan Institutional SULFAMYLON mafenide acetate CREAM;TOPICAL 016763-001 Approved Prior to Jan 1, 1982 3,497,599 ➤ Try a Free Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 5,466,700*PED ➤ Try a Free Trial
Mylan Institutional ULTIVA remifentanil hydrochloride INJECTABLE;INJECTION 020630-001 Jul 12, 1996 5,019,583*PED ➤ Try a Free Trial
Mylan Institutional RIMSO-50 dimethyl sulfoxide SOLUTION;INTRAVESICAL 017788-001 Approved Prior to Jan 1, 1982 3,549,770 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for MYLAN INSTITUTIONAL drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Injection 100 mg/mL, 2.5 mL vials ➤ Subscribe 2007-09-24
➤ Subscribe for Injection 1 mg/vial, 2 mg/vial and 5 mg/vial ➤ Subscribe 2013-12-27
➤ Subscribe Injection 1 mg/mL, 50 mL vials ➤ Subscribe 2011-12-16
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
Accenture
Moodys
Merck
Healthtrust
Covington
Queensland Health
Daiichi Sankyo
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.